Laddar populära aktier...
Redeye leaves a comment following today’s announcement by OncoZenge stating that Pharmanovia has dec...
Redeye comments on Jumpgates Q3 results, which was in line with our forecasts regarding sales and ma...
Beyond Frames reported net sales that were 8% lower than Redeye's estimate.
Redeye’s first comments on the Q3 report this morning.
Redeye updates its view on Flexion Mobile following its Q3 2024 report, which was largely in line wi...
Största ägaren Symrise lägger ett bud om 350 kronor per aktie i syfte att förvärva hela bolaget.
Björn Borg (“Björn Borg”, “the Company” or “the Group”) is a well-established and renowned company w...
Luxbright (”Luxbright” eller ”Bolaget”) fortsätter att uppvisa starkt momentum med flera framgångar ...
Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period th...
Q3: 18% ARR growth vs. ABGSCe 19.5%, FCF slightly lower '24 guidance modified yesterday - lower ARR,...
Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being develope...
Redeye updates its fair value range following Friday’s Q3 report and after the outcome of the extra ...
We cut '24e-'26e adj. EBITDA by 13-9% Shareholders accept the large divestment '25e EV/EBITA ~5x Wh...
Redeye provides a research update following the Q3 report recently published by Coegin Pharma.
Den 6:e november kommenterade Analysguiden iZafes rapport för det tredje kvartalet.